University of Miami Miller School of Medicine, Florida 33136, USA.
Am J Respir Crit Care Med. 2010 Dec 1;182(11):1344-51. doi: 10.1164/rccm.201001-0038PP. Epub 2010 Aug 13.
Endothelial dysfunction in the extrapulmonary circulation has been linked to cardiovascular disease. Recent investigations have revealed that in the airway circulation, cigarette smoking, chronic obstructive pulmonary disease (COPD), and asthma are also accompanied by endothelial dysfunction. Inhaled glucocorticosteroids can partially or fully restore normal endothelium-dependent vasodilation in these conditions, thereby identifying the airway endothelium as a novel therapeutic target in the treatment of airway disease. The role of the defective endothelium-dependent vasodilation in the pathophysiology in asthma and COPD is still subject to speculation. However, there appears to be an association between COPD and extrapulmonary vascular dysfunction, and the possibility exists that the use of inhaled glucocorticosteroids has a beneficial effect on cardiovascular disease in COPD as suggested by database studies showing that inhaled glucocorticosteroids reduce the incidence of nonfatal and fatal cardiovascular events in COPD.
肺外循环中的内皮功能障碍与心血管疾病有关。最近的研究表明,在气道循环中,吸烟、慢性阻塞性肺疾病(COPD)和哮喘也伴随着内皮功能障碍。吸入性糖皮质激素可以部分或完全恢复这些情况下正常的内皮依赖性血管舒张,从而确定气道内皮作为气道疾病治疗的新的治疗靶点。在哮喘和 COPD 中,功能失调的内皮依赖性血管舒张在病理生理学中的作用仍存在推测。然而,COPD 似乎与肺外血管功能障碍有关,并且可能存在这样一种可能性,即数据库研究表明吸入性糖皮质激素可降低 COPD 中非致命性和致命性心血管事件的发生率,提示吸入性糖皮质激素对 COPD 中的心血管疾病有有益的影响。